Introduction
factors, most obviously the immune system [5 ] , that are genetically specified and can show wide functional variation between different individuals. Human diseases result from complex interactions between genetically-determined biological mechanisms Enormous effort is now being focused on identifying the genes and mutations associated with predisposition and the environment. Genetic effects are most apparent in diseases such as cystic fibrosis, muscular dystrophies to common diseases in the expectation that this will provide key insights into the underlying pathophysiology or Huntington's disease that are inherited in a Mendelian fashion. Inherited susceptibility to more common human as well as generating DNA-based diagnostic and prognostic tools to assist physicians in selection of diseases including hypertension, diabetes, arthritis, and different types of cancer is less obvious, and is more appropriate therapies. Considering that the gene responsible for Huntington's disease, a Mendelian disorder, likely to be obscured by environmental influences such as diet and smoking. Nevertheless, the importance of was not identified until 1993 [6 ] , some 10 years after the trait had been mapped to chromosome 4, it may genetic determinants is now widely accepted [1-4 ]. Even infectious diseases, which clearly have a strong seem optimistic to consider attempting the far more complex task of mapping and cloning genes that merely environmental component, occur in the context of host contribute a predisposition to common diseases [7 ] .
genetic map with an average marker density of 2-5 centimorgans [ 13] . In fact this was achieved a year Yet there have already been striking successes, notably in Alzheimer's disease, and breast cancer [8] [9] [10] [11] [12] . This ahead of schedule [ 14] . Nine hundred and seventy markers were positioned accurately to provide a framehas been made possible by significant recent advances in key areas of genome research.
work map with an average density of 4 centimorgans. Almost 5000 additional markers were mapped to a lower confidence level to give an overall average density of 0.7 centimorgans. Production of this map was a major milestone in Recent progress in genomic research genome research, providing a universal tool for mapping disease loci to relatively small genomic intervals, using Genetic maps a standard set of reagents. This resource will be crucial for the identification of genes causing predisposition to Mapping and identification of disease genes by linkage analysis usually begins with a systematic genome-wide complex diseases. search for chromosomal regions that are frequently co-inherited from affected progenitors along with the disease phenotype. This requires DNA markers, from
Sequencing the human genome known chromosomal locations spread evenly across the genome, that can be used to distinguish between DNA The major goal of the Human Genome Project was to sequence all 3 billion base pairs of human genomic inherited from affected and unaffected parents (Figure 1 ) . A high-density map of informative markers is also DNA by 2005 [13 ] . This appeared wildly optimistic to many observers, seemingly requiring dramatic improverequired for other types of genetic analysis such as sibpair analysis and linkage disequilibrium mapping. ments in contemporary technology. Yet it is now being suggested that 99% of the human genome could be At the outset of the Human Genome Project in 1990 one of the immediate objectives, scheduled for comsequenced to 99.9% accuracy, within only 5 years, simply by scaling up currently-available methods [ 15] . pletion during 1995, was the production of a human Fragments containing microsatellite repeats are amplified from genomic DNA by PCR, using primers that hybridise to the unique, constant regions flanking the variable sequence. The example shown is a di-nucleotide repeat but tri-and tetranucleotide repeats are also used. The unique regions identify the chromosomal location containing the marker. PCR products are sized by gel electrophoresis to reveal the size of the repeated region. This marker reveals that son D inherited the disease from his affected mother (A) along with the maternal chromosome carrying the 20-CA repeat unit. The three unaffected children inherited the maternal chromosome carrying a 22-CA repeat unit. (Filled symbols=affected; open symbols= unaffected; circles=female; squares=male). Typically, hundreds of such markers covering the entire genome are tested in large numbers of families to obtain evidence that certain chromosomal regions are co-inherited with the disease more often than would be expected by chance.
Determination of the entire genome sequence will at around 1000 at the end of 1994, increasing to over 10 000 by the end of 1995 and is expected to exceed identify the complete repertoire of human genes and their chromosomal locations. However, since most of 20 000 by the end of 1996. As new susceptibility loci are identified, the transcript map will indicate which genes the genome (around 97%) consists of non-transcribed DNA, genomic sequencing is considered to be a are already known to lie in the region of interest, providing an immediate list of candidates to be screened relatively inefficient means of identifying protein-coding genes. An alternative approach is to sequence cDNAs, for disease-associated mutations. The ultimate transcript map will be provided by the which are derived only from the transcribed portion of the genome. cDNA libraries, prepared by in vitro completion of the entire human genome sequence, possibly by the year 2001. This will identify any genes reverse-transcription of mRNA extracted from particular organs or cell-types, not only provide a rich source of not previously mapped as ESTs, including structural RNA genes, and genes expressed at very low levels, that protein-coding sequences, but also information about patterns of gene expression in different tissues. A number are less likely to be represented in cDNA libraries.
At the current rate of progress there is every likelihood of commercial organisations and academic consortia are pursuing this approach vigorously in the expectation that the large majority of human genes will have been sequenced and assigned to chromosomal loci within the that this will lead to the identification of novel genes with therapeutic potential. next 2-3 years and that many of the genetic mutations associated with inherited susceptibility to common DbEST, the largest public-domain sequence database, is expected to contain over 400 000 partial cDNA diseases will also have been identified. Information such as this is already proving valuable in the search for new sequences (also known as ESTs-Expressed Sequence Tags) by the Summer of 1996. The vast majority of therapeutic targets and treatments. these have been contributed by a sequencing programme at the University of Washington in St Louis supported by Merck and Co. Ltd. It is not straightforward to calculate how many of the estimated 60 000 to 100 000
Genes and new medicines protein-coding genes in the human genome are represented in DbEST because it is possible to generate Protein therapeutics several non-overlapping EST fragments from a single, full-length cDNA. However, as of May 1996, DbEST Despite pharmaceutical companies' historical preference for small molecules, by 1993 five of the top twenty contained around 45 000 distinct groups (clusters) of sequences. In the best possible case this could represent pharmaceuticals were proteins, based on sales. The world-wide market for 'biopharmaceuticals' expanded 45 000 individual genes, although the actual number is likely to be somewhat lower.
from just 5% of the total pharmaceutical market in 1992, to 26% ($9 billion/year) in 1993 [18 ] . It has been Commercial organisations such as Incyte Therapeutics Inc. (Palo Alto, Ca., USA) and Human Genome Sciences predicted that the US market alone will increase from $5 billion in 1994 to over $15 billion/year by 2004 [ 19] . Inc. (Gaithersburg, Md, USA), have accumulated even larger private collections. The HGS database is reported cDNA databases and disease genetics programmes will provide a rich new source of novel protein to contain over 850 000 ESTs corresponding to perhaps 60 000 individual genes [16] .
therapeutics, and commercial organisations are racing to exploit this untapped potential. This approach is already beginning to bear fruit. Human Genome Sciences reported recently that they had received three US patents for full-length human genes involved in osteoporHuman transcript map osis, inflammation, and cell damage, and had another 150 gene patents pending. These genes were identified EST databases contain information about the relative abundance of particular cDNA sequences in different initially by analysis of the HGS cDNA sequence database. libraries, which can provide clues about tissue-specific processes contributing to disease pathology. Similarly, There are several precedents that attest to the patentability and commercial potential of protein therachanges in gene expression associated with pathological conditions may be identified by comparing sets of peutics. Successful products such as recombinant human erythropoietin have provided valuable insights into the cDNAs isolated from normal and diseased tissues. These databases can also be used to find novel subtypes of issues involved in developing and marketing protein therapeutics, and there is no reason to believe that new receptors, growth factors and other proteins with known commercial importance. However databases per se are proteins will face any insuperable obstacles. Development of antimicrobial vaccines will also not particularly useful for establishing causal relationships between genes and disease.
receive added impetus from the microbial genome sequencing programmes currently underway or already The value of these cDNA collections would be further increased if they could be correlated with diseasecompleted. Interest in vaccine development has been heightened by the emergence of drug-resistant strains of susceptibility loci. A number of international collaborations are now involved in the production of a 'transcript pathogenic bacteria. The genomes of Haemophilus influenzae [ 20] and Helicobacter pylori (by Genome map' by establishing the chromosomal locations of selected ESTs [ 17] . The number of mapped ESTs stood Therapeutics Corp., Waltham, Massachusetts, USA) have already been sequenced. A number of organisations numbers and T-cell ADA levels were observed following retroviral-mediated ex vivo transfer of ADA cDNA into have expressed their intention to sequence additional pathogen genomes during 1996. Analysis of the sequence T-lymphocytes isolated from two ADA-deficient children. CFTR (cystic fibrosis transmembrane conductance data will be used to identify cell-surface proteins as candidate antigens for vaccine preparation, and potential regulator) cDNA has been delivered to the nasal epithelium (as an accessible surrogate for airway epitargets for the development of novel antibiotics. thelium) in human cystic fibrosis patients, using adenoviral vectors and plasmid-liposome complexes. Partial correction of the abnormal ion-transport phenotype was Gene therapy obtained for 1-2 weeks using both viral and non-viral delivery [23, 29 ] . After the excitement of encouraging early results [21 ] , gene therapy now appears to be suffering the conseUnfortunately, it has not proved possible to achieve such positive results consistently, and many problems quences of over-optimistic initial expectations. Results from several studies have failed to show clinical benefit remain. There have been reports of inflammation and immune responses associated with the use of adenovirus to treated patients despite evidence that gene transfer and expression had been achieved to a certain extent in vectors. The possibility of producing replication competent viruses (by recombination) in therapeutic prepthe target tissue [22 ] . It may be argued that some of these patients had proven resistant to conventional arations of supposedly 'safe' retrovirus and adenovirus derivatives continues to be a concern. Plasmid-liposome treatment, or were in advanced stages of disease. Furthermore in some of these trials, including treatment mediated delivery has the advantage that no infectious agents are used, but the gene transfer efficiencies of patients suffering from familial hypercholesterolaemia and adenosine deaminase (ADA) deficiency, other achieved so far have been disappointing. Gene therapy has attracted enormous investment of therapies were being coadministered. Demonstrating clinical benefit attributable to the gene therapy is likely effort and capital, notably from some of the major pharmaceutical companies, and there seems little doubt to be particularly demanding under these circumstances.
The fact that gene transfer and expression have been that, in the longer term, this approach will have a significant impact on the treatment and prevention of achieved in target cells does provide cause for optimism. Evidence for gene transfer has been obtained in 28 ex human diseases. Nevertheless, it is clear that significant improvements vivo studies (where patient cells are first removed from the body, treated with the gene preparation, then in targeted gene delivery and expression methodologies are required for clinical applications of gene therapy. re-introduced) and 10 in vivo studies [23 ] . Success has been achieved with each of the three major types of This was reflected in a recent report from a committee instituted by the U.S. National Institutes of Health vector preparation, using retrovirus, adenovirus, or plasmid-liposome complexes respectively, to mediate recommending greater emphasis on research applications of gene 'therapy' for identifying disease mechangene transfer (see Table 1 and [24] [25] [26] [27] [28] ). Furthermore, appropriate biological responses have been observed in isms and development of improved animal models, with less emphasis on clinical applications. some of these trials [23 ] . Increases in circulating T-cell Insights into pathogenesis common diseases, including hypertension. Two important consequences are that it will become possible (a) to redefine disease by mechanism rather than merely by Despite decades of biochemical and pharmacological investigation, the mechanisms underlying many common description of the phenotype and ( b) to develop novel, mechanism-based therapies targeted at subsets of diseases, particularly those affecting the central nervous system, have remained elusive. Increasing emphasis is patients most likely to show a favourable response. now being placed on establishing the molecular basis of inherited disease susceptibility as a means of gaining insight into the pathophysiological processes involved.
Genetic subdivision of disease and consequences for therapy Alzheimer's disease (AD) provides an example of this approach.
Mutations leading to development of AD were first It is clear that in many diseases the observed 'phenotype' may result from dysfunction in any one of a number of identified in the amyloid precursor protein (APP) gene on chromosome 21 [8 ] . This is a comparatively rare different biological systems. For example, severe hypertension may result from excess fluid retention, dysfunccause of AD, with only 11 families in the world known to be affected by mutations in APP [30] . Subsequently, tion in the renin-angiotensin system (RAS), and other factors that affect smooth muscle tone. Although it was shown that more than 60% of all cases of AD are associated with alleles of the ApoE gene, which is diuretics, angiotensin-converting-enzyme inhibitors, or b-adrenoceptor blockers may be used to treat subsets the major susceptibility gene for late-onset disease [31 ] . The role of ApoE in the pathology of AD is not of hypertensive patients, none of these treatments is effective in all hypertensive individuals. understood, although it is known that the ApoE4 allele is associated with increased risk, whereas the E2 allele Heterogeneity such as this is evident in other common diseases but, to date, it has been difficult to identify the appears to be protective.
Early-onset autosomal dominant AD accounts for different mechanisms giving rise to the common phenotype, and to select subsets of patients likely to respond less than 5% of all Alzheimer's patients. However, closer correlation of phenotype and genotype in rare to particular treatments. This is beginning to change as a result of information coming from molecular genetics Mendelian variants of complex diseases makes them more amenable to genetic analysis compared with the programmes. Multiple susceptibility loci have been mapped for hypertension, Type I and Type II diabetes, more common forms. The advantages of this approach were demonstrated in June of 1995, when it was reported schizophrenia, breast cancer, colon cancer, rheumatoid arthritis, and as noted above, Alzheimer's disease. that mutations in a gene designated 'S182' (subsequently renamed presenilin-1), on chromosome 14, co-segregated
In contrast to Alzheimer's disease, major mechanisms involved in control of blood pressure have been with the disease in certain families [9] .
This sparked furious activity in Alzheimer's research. characterised biochemically and pharmacologically. Nevertheless the pathogenesis of hypertension remains The value of EST databases, when correlated with genetic information, was rapidly demonstrated by the unknown in the overwhelming majority of patients [ 1], because of complex interactions between different discovery that S182 had sequence homology to a number of other human partial cDNA sequences. One physiological pathways. Recent studies have identified genetic variants in a of these was mapped to a region of chromosome 1 known to be associated with early-onset AD disease in small proportion of patients with essential hypertension (which accounts for 95% of all hypertensive patients) another small group of patients [10 ] , and it was shown that mutations in this gene, 'STM2', cosegregated with [33] , and other mutations responsible for rare Mendelian disorders of blood pressure regulation. This the disease in the affected families. By the following September it had been reported that a novel gene information can be used to begin grouping subsets of hypertensive patients according to the nature of the involved in intercellular signalling in the nematode Caenorhabditis elegans, also had sequence homology to genetic lesion, as described below. Certain alleles of the angiotensinogen gene are S182 [32] . Since there are human homologues of other components of this pathway, it should be possible to associated with elevated plasma angiotensinogen levels [33] . Overexpression of angiotensinogen in transgenic use C. elegans as an experimentally amenable model to establish the function of S182 and its role in cellular animals has been shown to correlate with increased blood pressure [34 ] presumably because of the consesignalling.
Thus, the report describing a susceptibility gene quent overproduction of the active vasoconstrictor angiotensin II (A-II) (Figure 2 ) . A-II binds to vascular affecting a relatively small number of Alzheimer's patients led, within a period of 4 months, to the receptors causing vasoconstriction, and to receptors on the adrenal glomerulosa, activating production of identification of an additional AD susceptibility gene, recognition of a family of related human genes, and the mineralocorticoid, aldosterone. Aldosterone activates the kidney amiloride-sensitive sodium channel identification of an experimentally amenable system that may provide crucial insights into a fundamental pathway (indirectly, acting through mineralocorticoid receptors) which stimulates sodium reabsorption, causing increased governing cellular interactions.
Ultimately, information such as this will define the plasma volume and, as a consequence, elevated blood pressure. A-II also has a direct effect on sodium mechanisms involved in Alzheimer's disease at the molecular level. This is already happening in other reabsorption, mediated by A-II receptors on kidney tubules. A feedback mechanism in the kidney responds I (PHA-1 ) [37, 38] . In the latter disease, treatment includes sodium chloride supplementation and dialysis to increased plasma volume by suppressing renin secretion, resulting in a reduction in circulating A-II to reduce hyperkalaemia. Death is common in the neonatal period if the disease is not diagnosed. levels, and consequent fall in aldosterone production [reviewed in 1 ].
The different mechanisms causing hypertension in these patients have different therapeutic consequences. However, in glucocorticoid-remediable aldosteronism (GRA), a rare Mendelian trait, hypertension is caused Hypertension resulting from overproduction of angiotensinogen should respond to agents active against the by a gene duplication event that places an additional copy of the aldosterone synthase gene under the control RAS, to reduce the effects of A-II at vascular, adrenal and kidney receptors. Although specific antagonists of the of promoter elements from the 11b-hydroxylase gene, which is regulated by adrenocorticotropic hormone amiloride-sensitive sodium channel should reduce sodium reabsorption in these patients, this would not control (ACTH), not by A-II. Hypertension in individuals carrying this mutation is caused by sodium reabsorption vasoconstriction mediated by vascular A-II receptors. Although RAS inhibitors should reduce sodium driven by excess aldosterone. The feedback mechanism involving the RAS is ineffective because reduction in reuptake mediated by kidney angiotensin receptors, this has an insignificant effect in GRA patients, in whom circulating AII has no effect on production of aldosterone from the mutant fusion gene [1 ] .
sodium absorption is mediated primarily by ACTHinduced overproduction of aldosterone. Instead, GRA The kidney amiloride-sensitive sodium channel is a key regulator of sodium balance and mutations affecting may be treated with glucocorticoids, which suppress ACTH secretion; by specific antagonists of the kidney the activity of this complex can cause opposite phenotypes. In Liddle's syndrome, constitutive activation of mineralocorticoid (aldosterone) receptor; or by antagonists of the kidney epithelial sodium channel, that controls the channel by mutations in the genes encoding the b or c subunits results in excessive sodium reabsorption, sodium re-uptake in response to aldosterone [1 ] . Patients with Liddle's syndrome, unlike those suffering leading to hypertension [35, 36 ] . Different mutations in the a or b subunits cause loss of sodium channel from GRA, respond only to the last of these three therapeutic options, since the sodium channel is constifunction, resulting in salt wastage and hypotension, in patients suffering from pseudohypoalderosteronism type tutively active and unresponsive to aldosterone.
Genetic tests may now be used to identify patients certain drugs. Known examples include alleles of the CYP2D6 and CYP2C19 genes that correlate with suffering from hypertension due to the different mechanisms described above, allowing early selection of the most altered metabolism of a wide range of compounds. In affected individuals, standard doses may result in plasma appropriate therapeutic options currently available. This approach will not have a significant effect on the overall drug levels that are too low to produce the desired therapeutic effect or that reach concentrations more management of hypertension in the short term since the Mendelian disorders account for only a small proportion likely to produce side-effects [reviewed in 39 ]. CYP2D6 catalyses metabolism of a wide range of of all hypertensive patients. However, as more of the genes contained in known susceptibility loci for hypertenlipophilic drugs, including b-adrenoceptor blockers (e.g. propranolol), antiarrhythmics (e.g. propafenone), antidesion and other common diseases are identified, DNAbased tests will become an increasingly powerful means pressants (e.g. imipramine, fluoxetine), neuroleptics (e.g. haloperidol) and others such as codeine and of identifying sub-groups of patients for whom particular therapies are more likely to be successful.
debrisoquine. The B allele of this gene, which causes a pronounced poor metaboliser (PM) phenotype, is found at a frequency of around 7% in Caucasians. This allele is Commercial implications of mechanism-based therapies much rarer in Oriental populations where the frequency of poor metabolisers is only 1%. Poor metabolisers are The most immediate application of genetic information will be in clinical trials of compounds already under more likely to develop adverse reactions to drugs such as neuroleptics, relative to extensive metabolisers. development, to determine empirically if efficacy or adverse reactions correlate with any mutations in known
In contrast, as many as 50% of CYP2D6 alleles found in Oriental populations are accounted for by a gene genes. This will evolve into directed development of drugs targeted against specific mechanisms identified variant encoding a partially-deficient 2D6 enzyme in which proline residue 34 is mutated to serine [40 ] . This following the discovery of common disease-susceptibility genes. The problem for the pharmaceutical industry is results in a lower mean CYP2D6 activity in Oriental people compared with Caucasians, which accounts for that some diseases may be caused by a number of essentially independent mechanisms that, unlike the their relatively slower metabolism of antidepressants and neuroleptics and the lower doses that are used as a RAS and steroid pathways in hypertension, do not interact or converge. If this proves to be common, the consequence [ 39] . Gene amplification events can produce the opposite logical consequence is that targeted therapies may have to be developed for each distinct mechanism. effect i.e. the rapid metaboliser phenotype. A patient who required 3-5 times the normal dose of the On the face of it, the prospect of developing a series of novel drugs targeted at the different mechanisms antidepressant nortriptyline was found to have an extra, active, copy of the CYP2D6 gene [ 41] . Amplification leading to a disease, instead of having a single therapy aimed at treating the symptoms, does not appear an events resulting in as many as 12 functional copies of CYP2D6 have been reported, producing an even more attractive proposition, because the increased development costs will not be matched by a corresponding dramatic rapid metaboliser phenotype [42 ] . Intra-and inter-ethnic differences in metaboliser increase in market size. However, there are advantages. Since genetic tests can be used to identify those patients phenotypes have also been reported for CYP2C19 [ 43] , which is involved in the metabolism of drugs such as most likely to respond to a novel mechanism-specific drug, it should be considerably more straightforward to omeprazole (proton pump inhibitor), diazepam (anxiolytic), imipramine and propranolol. demonstrate efficacy. Therefore clinical trials could be smaller, with corresponding cost savings. Novel, effective, Genetic testing for disease-susceptibility alleles in clinical trials can be coupled with tests for alleles mechanism-based drugs should appear attractive both to the regulatory authorities, and to the medical associated with altered drug metabolism, or allergic responses, to account for individuals who experience community. Patients unsuited to a particular treatment would be spared unnecessary risk of side-effects.
adverse reactions or failure to respond to the standard dosage. Furthermore, the availability of reliable genetic diagnostic tests may allow identification of previously undiagLogically, this should be extended into the general population, so that patients can be offered tests to nosed or mis-diagnosed sections of the population that would stand to benefit from new therapies, maximising identify the treatments most likely to be effective and to predict their expected rate of metabolism of any drug effective market size. All of these factors should help to ameliorate the negative commercial implications of with a narrow therapeutic window. This would seem particularly appropriate in the ethnically-diverse popugenetically subdividing patient populations.
lations typical of modern societies where pronounced differences in metaboliser phenotypes are to be expected. Such tests need be performed only once, and would Pharmacogenetics become part of the patients' records. Genotypes known to be associated with poor metaboliser phenotypes Genetic tests for mutations in disease-susceptibility genes can also be used to screen patients for variants of should encourage caution on the part of the medical practitioner, in selecting the initial dosage. A rapid cytochrome P450 genes associated with adverse reactions, or failure to respond to therapeutic doses of metaboliser genotype would indicate that failure to achieve a therapeutic effect at standard dosages might incorporated into the primer, since these dideoxy derivatives lack the 3∞-hydroxyl group required for be remedied by increasing the dose rather than by trying another drug.
formation of phosphodiester bonds. Template-directed incorporation of chain terminator in any of the reactions Current molecular genetics and cDNA sequencing programmes are providing an extensive collection of is detected using a conjugated antibody detection system that gives a colourimetric readout. genes involved in drug uptake, metabolism, and clearance, as well as novel genes associated with allergic
Other methods for detecting known mutations include hybridising allele-specific oligonucleotides (ASOs) to reactions. It seems inevitable that increased application of genetic testing in clinical trials, using such information, immobilised samples of test DNA, and the oligonucleotide-ligation assay (OLA) [ 46] . will establish strong correlations between genotype, efficacy and adverse reactions. This will strengthen the Substantial numbers of patients can be screened for single, known genetic polymorphisms by such methods. case for personalised dosing regimes since it should become possible to predict more accurately the dose However, the large number of mutations that have been identified in disease susceptibility genes poses a major required to achieve safe, therapeutic, serum drug levels in individuals carrying particular combinations of genproblem for large screening programmes. More than 500 mutations are known to occur in the cystic fibrosis etic mutations. Clearly there is great potential for achieving marked improvements in patient care but the transmembrane conductance regulator (CFTR) gene [47] and over a hundred have been found in BRCA1, implications for general medical practice are considerable. It is recognised that providing genetic testing on one of the genes conferring susceptibility to breast cancer [ 48] . Most of the mutations in CFTR are the scale required will be a major challenge, and a number of different approaches are being developed in relatively rare and are usually ignored in genetic testing programmes. Nevertheless, screening large numbers of an attempt to meet the expected demand.
individuals only for the 'important' mutations remains a daunting task. An alternative approach is to completely resequence the test gene. This should identify known and novel Genetic testing mutations, and will be particularly important if previously undetected mutations modify the effects of T rends in genetic testing technology known sequence variants. However, complete resequencing is a relatively slow, laborious and expensive Until recently, application of genetic testing was restricted largely by the relative lack of information about procedure using conventional equipment. Although commercially-available automated DNA sequencers can genetic polymorphisms, but also by technological limitations. Development of the polymerase chain reaction generate around 200-300 bases of sequence data from each of 36 samples in a 2 h run, it may be necessary to (PCR) was a major advance that made it possible to isolate fragments of human genomic DNA in reasonably amplify and analyse several fragments from each gene to determine the complete sequence, particularly if the large quantities, without the need for molecular cloning [ 44, 45 ] . PCR continues to be the most commonly used coding region is distributed across a large number of exons. Improved automation of the steps involving amplification procedure, although alternative methods that avoid the requirement for thermal cycling have DNA extraction, template generation, enzymatic sequencing reactions and automated sample loading would been developed subsequently.
Following amplification of the region of interest from make this a more attractive option, but still relatively expensive. patients' DNA, screening for variation at known polymorphic sites can be performed by a number of different Microchip technology may provide an acceptable solution. A number of commercial organisations are methods, two of which are illustrated in Figure 3 . The upper panel depicts a PCR-based method where one of developing microchips capable of resequencing known genes completely [ 49] . Each glass or silicon chip the pair of PCR primers corresponds to a specific, known allele of the polymorphic site. Additional primers, contains a gridded array of oligonucleotides corresponding to overlapping sequences covering the length of a corresponding to other possible variants at this site, are used in parallel reactions. Amplified products of the target gene. Fluorescently-labelled test samples amplified from blood or saliva are incubated with the chips to expected size are obtained only if the allele-specific primer corresponds exactly to a sequence present in the produce a pattern of hybridisation that can be measured using a laser chip-reader. Mutations are detected by test sample. Production of amplified fragments from two different primers indicates that the individual tested comparing the hybridisation patterns obtained from test samples to that expected from the wild-type gene was heterozygous at the test site. Successful priming events can also be detected by measuring incorporation (Figure 4a ). Each chip has sufficient capacity to resequence several entire genes simultaneously in a single of radiolabelled dATP into the PCR products.
In the second system shown in Figure 3 an oligonucleindividual or to screen for major known mutations only (Figure 4b ). otide primer is enzymatically extended by one base across a polymorphic site, in four parallel reactions
Resequencing genes by hybridisation to gene-specific oligonucleotides can also be performed by the reverse containing individual dideoxynucleotide chain terminators (ddA, ddC, ddG, or ddT). No additional bases procedure where the PCR-amplified gene fragments are arrayed on nylon membranes, followed by sequential can be added once the chain terminator has been
Template Panel A: Allele-specific PCR priming Primer 1 can be extended to give PCR product
Template Primer 2 will not produce PCR product because of mismatch
Figure 3 Methods for detecting sequence polymorphisms
Panel A PCR-based polymorphism screening on genomic DNA. Primer 1 (top strand) can be extended and will yield a PCR product on this template, in combination with a suitable second primer. Primer 2 is extended very inefficiently because of the mismatch at the 3'-terminal residue and will not yield a PCR product. Detection of a product with Primer 1 but not with Primer 2 identifies the residue present in the template DNA at this position. Detection of products with both primers indicates that the individual is heterozygous at this position. Panel B Enzymatic extension of the single primer is performed in four parallel reactions containing one of the four dideoxynucleotide chain terminators. Incorporation of one of the four bases, determined by the template sequence, is detected using a conjugated antibody system giving a colourimetric readout.
hybridisation of radio-labelled, or fluorescently-labelled devices such as these would be fast enough to allow point-of-care testing for a wide range of mutations. A oligonucleotides to the arrays [50 ] . Over 20 000 PCR fragments can be gridded and sequenced in parallel on diagnostic technology that can simultaneously analyse DNA from 500 patients for 106 different mutations in a single 22×22 cm membrane. Hybridisation patterns are recorded and decoded to produce the sequence seven genes was described recently [51 ] . The fact that some of these systems are about to become available, information.
The US Department of Commerce has awarded and could be used to select patients most likely to respond to particular treatments, will create pressure grants totalling over $50 million to a number of biotechnology companies for the development of genetic for pre-prescription genetic testing to be used for an increasing number of diseases, with profound consediagnostics based on microchip and other advanced technologies. The goal is to develop systems that are at quences for medical practice. least ten times cheaper than those now in use (e.g. currently $100-$200 per test for cystic fibrosis) and which are convenient enough to encourage widespread Ethical concerns use.
Already, prototypes of miniaturised, high-speed PCR Offering genetic tests to patients already displaying disease symptoms, should be relatively uncontroversial. instruments are reported to have achieved cycle times of less than 25 s, reducing the time taken for a typical Test results would be used to support or refine a medical diagnosis, and to provide additional data about the amplification from around 2 h to less than fifteen minutes. Devices that allow PCR-amplification and suitability of different therapies. In the absence of the test, diagnosis and prescription would have to be made analysis of the reaction products to be performed directly on microchips are in development. One such anyway, but with less information available. Presymptomatic testing is rather different. Prosystem is planned to incorporate DNA extraction, isothermal amplification, and 'dip-stick' detection of phylactic treatment or early therapeutic intervention can be crucially important in many common diseases target sequences, in a self-contained, disposable cartridge, all for $5.00 per assay. If reduced to practice, and the benefit from early diagnosis is obvious. For a b COLOUR FIGURE Figure 4 Mutation detection using high-density oligonucleotide arrays A set of overlapping oligonucleotides, completely spanning the sequence to be tested, are synthesised directly on glass or silicon chips (each small square in the figure above corresponds to a cell containing one oligonucleotide sequence). A fragment to be resequenced is amplified from genomic DNA, and used to prepare a fluorescent probe that is hybridised to the chip. Strength of hybridisation of the probe to each oligonucleotide is visualised as fluorescence intensity using a laser 'chip-reader', and the pattern of fluorescence is decoded to reconstitute the sequence of the original fragment (top panel). Chips can also be designed specifically to detect major known mutations such as the DF508 mutation in cystic fibrosis transmembrane conductance regulator ( bottom panel). Photographs courtesy of Affymetrix, Palo Alto, CA.
some diseases, an early positive diagnosis may require ing effect than a positive test result. It may be possible to derive greater benefit from testing for such diseases nothing more than alteration of lifestyle, so that individuals who find that they have a genetic preby using psychological profiling to select those patients most able to cope with the trauma of a positive disposition to hypercholesterolaemia, or emphysema, would be well advised to avoid risk factors such as diagnosis. Nevertheless, there is now a strong consensus against smoking. However, a positive test result for an allele known to confer a high risk of cancer, or Alzheimer's the use of genetic screening for diseases where no effective therapy exists. There is also agreement that disease has far more serious implications.
As more disease susceptibility genes, and their causagenetic testing should not be performed unless it is accompanied by counselling on the significance of test tive mutations, are identified, the pressure from some concerned individuals to have such tests performed will results. However, many commentators doubt the feasibility of providing suitable counselling on the scale required increase. Advertisements offering genetic testing directly to private individuals have already appeared in the should screening become widespread. These issues will remain at the forefront of the debate on presymptomatic national press in the UK and USA.
Unfortunately, our ability to perform these tests is genetic testing, for the foreseeable future. already outstripping our ability to understand the biological relevance of the results. For predictions of disease risk based on pre-symptomatic genetic testing Genetic discrimination to be acceptable there must be clear correlation between known mutations and clinical consequence. Yet this is
The potential for misuse of genetic information continues to give cause for concern. A number of surveys have rarely the case. Even in cystic fibrosis, which is inherited as a Mendelian autosomal recessive trait, there is confirmed that families affected by diseases with obvious patterns of inheritance (e.g. Huntington's disease) have evidence for heterogeneity in the phenotype expressed by individuals carrying identical CFTR mutations [52 ] .
difficulty obtaining health insurance [51 ] . One study reported that 22% of a group of 332 people who had a The vas deferens is functionally disrupted in nearly all males suffering from CF, whereas the degree of pancregenetic illness in their families had been refused health insurance. Insurance companies can already identify atic insufficiency is determined by the patient's genotype. However, the severity of pulmonary symptoms correlates some people at risk from serious inherited diseases by requesting information about the health, or cause of poorly with genotype, presumably because of other genetic or environmental factors that influence lung death, of parents and siblings. Availability of genetic tests for diseases with more complex inheritance patterns function.
Similarly, the likelihood of developing a complex may exacerbate this problem. Some insurers have regarded disclosure of a susceptible genotype as being disease, and the severity of the symptoms, may vary enormously in individuals carrying identical mutations 'evidence of pre-existing disease'. Over half of a group of 917 people who were at risk from an inherited disease in known susceptibility genes. Family pedigrees selected for genetic linkage analysis tend to be those that show reported that they had suffered discrimination after revealing a genetic diagnosis [51 ] . the clearest predisposition to the disease. It may be that because of their genetic background, these individuals Early diagnosis and appropriate monitoring or prophylactic treatment can have a considerable impact are far more susceptible to the effects of the causative mutation than members of the general population.
on morbidity and mortality associated with many common diseases, and also considerable potential for Therefore it may be necessary to restrict the use of presymptomatic genetic tests initially to those families in reductions in the cost of healthcare provision. Patients who know that they have inherited susceptibility to which a clear correlation between mutations and clinical outcome has been established. Eventually, it will become colon cancer, for example, can ensure regular screening, and can opt for removal of the colon at the first sign of possible to identify combinations of mutations in groups of genes, that do accurately predict development, pre-cancerous changes. Paradoxically, insurance companies may miss an opportunity to cut their healthcare progression and severity of inherited disorders, but that lies years in the future.
costs, since many individuals who could derive benefit from early diagnosis, and avoid the need for extensive There is considerable debate about whether presymptomatic genetic testing should be restricted to surgery and hospitalisation, may decline to take appropriate tests if disclosure of a positive result may result those diseases for which an effective therapy exists. There have been well-documented cases where positive in subsequent refusal of insurance coverage. Concerns such as these have persuaded scientists, tests for Alzheimer's and Huntington's diseases, for which no effective treatment exists, have driven some doctors, patients and other groups to press for laws preventing insurers from denying coverage on the basis patients to the brink of suicide. Yet, in one study involving 135 patients it was found that, a year after of genetic information. Legislation has already been enacted by several US states. US Federal law prohibits testing, the group that had had a clear result in a genetic test for Huntington's disease (37 positive plus 58 genetic discrimination in employment and recently both the US Senate and House of Representatives passed negative) scored higher on psychological tests of wellbeing and lower on tests for depression, than the 40 health reform bills including 'genetic information' as a factor that may not be used to deny insurance coverage. patients whose test results were ambiguous [53 ] . For many individuals, uncertainty may have a more debilitatSimilarly, among European countries, France, Belgium and Norway have laws preventing the use of genetic PCR (Polymerase Chain Reaction):-a method for amplifying DNA fragments using repeated enzymatic exteninformation in life and medical insurance.
sion of a pair of specific primers. Phenotype: Physical manifestation (e.g. hypertension) of genetic traits. Physical map: Figure showing the actual physical Conclusion locations of cloned genomic DNA fragments relative to chromosomes. There are sets of overlapping cloned Information from genomic research offers the potential for enormous improvements in medical practice, not genomic DNA that entirely cover some chromosomes, such as 21. only by providing new therapeutic targets and treatments, but also through the use of genetic testing to Polymorphism: Inherited DNA sequence differences between individuals. target therapies to appropriate patients.
Realisation of this potential may be delayed, or even Positional cloning: Isolation of genes according to their position on a chromosome, rather than by sequence or prevented, by concerns about the exploitation of genetic information and by premature application of genetic function.
Transcript map: A table giving the chromosomal testing methodologies before the consequences have been fully considered. Open and informed debate locations of genes that are expressed i.e. transcribed into mRNA. including scientific, medical, commercial, lay, ethical and legislative representation is urgently required to ensure that safeguards agreed to be necessary are put in place. Provision of extra resources for counselling on the References significance of genetic test results, and strong legislation to reassure the general public that genetic information
